Oncomatryx Biopharma Alternatives & Competitors
12 companies similar to Oncomatryx Biopharma
Companies similar to Oncomatryx Biopharma
Stellanova Therapeutics
Conquering Cancer
Houston, United States
Agensys
Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug...
ImmunoBiochem Corporation
Improving patient outcomes through innovations in biological therapeutics
Toronto, Canada
Iksuda Therapeutics
Creating class-leading ADCs with enhanced tumor specificity
Newcastle Upon Tyne, Unit...
Rival Readout
Competing with Oncomatryx Biopharma? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Vidac Pharma
New Paradigm in Cancer Drug Discovery: Dissociating HK2/VDAC and pro-immune Tumor microenv...
Ness Ziona, Israel
XenTech
Premium quality preclinical oncology CRO, pioneering the PDX technology for more than 16 y...
Evry, France
Antharis Therapeutics, Inc.
Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...
San Diego, United States
ONA Therapeutics
First-in-class ADCs tailored to attack advanced cancer
Barcelona, Spain
Pyxis Oncology
Charting a course to therapeutics for difficult-to-treat cancer.
Boston, United States
Tagworks Pharmaceuticals
Pioneer of Click-to-Release chemistry; designing more effective and safer systemic therapi...
Nijmegen, The Netherlands
Cytimmune Sciences
Developing safer more effective therapies that can attack tumors on multiple fronts simult...
Rockville, United States
About Oncomatryx Biopharma
Oncomatryx Biopharma is a biopharmaceutical company founded in 2009 and headquartered in Spain. Specializing in the tumor microenvironment, the company has developed precision drugs and diagnostic devices targeting the tumor stroma, including Antibody-Drug Conjugates (ADCs) and human-derived proteins that focus on peri...
Biopharmaceutical, Tumor Microenvironment, Precision Drugs, Diagnostic Devices, Antibody-drug Conjugates, Peritumoral Fibroblasts, Endothelial Cells, Extracellular Matrix, Immunosuppression, Pancreatic Cancer, Patient-derived Xenograft, Cancer-associated Fibroblasts, Therapeutic Index, Oncology, Drug Development
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Oncomatryx Biopharma: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Oncomatryx Biopharma on 11 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
